YCW25· OtherUncommon Therapeutics
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Founders
Not read from YC yet; the weekly run fills these in.
Same space
Competitors
Closest in what they build, same category.
Adjacent
Overlapping tags, a different niche.
NephrogenS20Curative genetic medicines for kidney diseasesShared: gene therapy, crisprActive
SFA TherapeuticsS21Regulating the immune system to block cancer & autoimmune diseasesShared: biotechnologyActive
FinalDoseX26Programmable DNA drug destroying all cancers, unlocking 80% of targetsShared: gene therapyActive
Andson BiotechW22Empowering Mass Spec for Biotech and BeyondShared: gene therapyActive
Eugit TherapeuticsS22Enabling Tissue Targeting of TherapiesShared: biotechnologyActive
Also from W25
Batchmates in Winter 2025.
.WaveW25Continuous inference for streaming AI modelsActive
10xW25AI Sales Teams for Dental PracticesActive
a0.devW25We make mobile apps using AI.Active
A1Zap by A1BaseW25The social network layer for AI appsActive
AdamW25AI Powered CADActive
AfterQueryW25Applied research lab curating data solutions for foundation model…Active
About Uncommon Therapeutics
Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.
San Francisco, CA, USA
Uncommon Therapeutics: questions
Which YC batch was Uncommon Therapeutics in?
Uncommon Therapeutics was in Y Combinator's Winter 2025 batch (W25).
Is Uncommon Therapeutics still active?
Y Combinator lists Uncommon Therapeutics as active.
Where is Uncommon Therapeutics based?
Uncommon Therapeutics lists San Francisco, CA, USA as its location on YC's directory.
Not affiliated with Y Combinator. From YC's public directory. Logos via logo.dev; trademarks belong to their owners.